Member Info for Gheko

Maybe that 50;004 share sale was the end of Maven as odd number.

Either way this coiled spring is about to pop up. Onwards and upwards.

I suspect last of the Maven stock which is good then they will be clear and away we go.

Great opportunity to keep top up buying then away we go.

Another pointless RNS by Cliff. Not newsworthy for an RNS. Maybe lining up another raise!

Yep buying pressure growing again. The re rate is on.

The silence is because something very serious going on behind the scenes hence no social media titbits from DL etc for a while.

We know how fast this share can move. Imagine it if the eventual news is announcement of major discovery and/or JV?

It will be straight into auction and come out at multiples of this. Pays your money and takes your chance.

Same for me m had to buy in smaller chunks but got them now and more to go.

The re rate is starting. If Malvern have any left then if they want to clear then this re rate will clear them out and then any short term drag is gone.

The FAB train is leaving the lull station and will be going full steam ahead.

Just try and get your head round just how huge Optimal is!! Best in class, disruptive and hugely valuable to big and small pharma alike.

Last chart action saw bounce from circa 12p to first stop 22p then 30p.

Just released funds from another share to buy more here as the action starting. Good luck all.

Apologies I should have out the link. Thanks gtc.

Like the “no news is good news” quote and “ that’s about all I can say at the moment”.

So much bubbling the cork is going to pop v soon 🚀🚀🚀

One catalyst for a surge at anytime is the Optiphage interest from a client who was after an exclusive deal. Adrian started to answer the question about this but then stopped himself so something happening.

Think contract news is going to come thick and fast.

Amatour- easily double this and in short term Im looking for 30p +. Medium term I think 50p will be a reasonable target as this snowballs.

Great summary gtc. Wakey Wakey market, once the re rate starts soon it will be quick and very profitable.

Onwards and upwards.

Rocka….. That was my question to him. He said that BOTH Fab and NCI want a deal so they continue to use the platform. Not in Fab’s interest or the NCIs to just pull the plug exactly on 2 year expiry.

Clearly a deal is being done and will be soon. The validation by the NCI of Ootimal is priceless and just as we launch Ootimal. Top timing!

I also liked his answer about the value if deals going forward. He agreed with a question that if a company wanted the full suite of Optimal from start to finish of a project then that is a £million project right there.

However many firms will want slices of that so there will undoubtedly be nice deals for FAB that are not published in an RNS he said and yet add nicely to revenue. He was very comfortable with the £1.5 million projection plus cash has gone up since year end. Happy days.

Get Malvern gone and we re rate just as the launch happens. Lovely.

Decent presentation. Company comfortable with analysts forecast of £1.5 million revenue. Cash position increased since year end.

All on track for optimal launch with significant interest pre launch.

Sees a big gap between where they are as a company and our current share price which should catch up with what we have.

All v positive.

I would say £65 million would be acceptable giving a SP of circa 60p a share.

Excited to hear from the company at 11am the level of interest already building for Optimal.

Mmhater…….. from my earlier pos5 I think this is a possibility but also teh other way round in that the NCI may want this all to themselves so want to buy us out before a big pharma does.

Not surprised re no contract signed yet as they are a government department and that’s always slow as well as teh US lockdown recently as mentioned in RNS today. However a good question for tomorrow’s investor presentation is what happens to the NCI having access to our platform after Friday if no deal signed as their free 2 year use runs out?

Either way the market must wake up soon to the massive value of Optimal that someone soon is going to want to take us out at a huge premium to secure it.

With the tiny micro cap of FAB at the moment and the NCI having used the Optimal platform for 2 years and clearly loving it, it can’t be beyond the possibility that instead of doing a deal to continue to use it they just take us out at a huge premium and own it for themselves.

Otherwise a major pharma may make their move and own it and the NCI could lose the use of this very valuable asset.

Once launched in a couple of weeks or so at the major conference attended by all the big players then the train will be getting a full head of steam and one of teh big pharma are going to see teh value and take us out first.

Just a thought. Either way the upside now is truly huge.

Investor presentation tomorrow to put even more meat on the bones. Think the excitement about the Ootimal launch will be palpable!

All on track and the NCI contract getting close. Launchpad for Ootimal all ready and already big pharma are sniffing around.

Excellent news.

Stt1…….what is the point you are making? Please re read what I suggested.

“And for all those reasons, folk buying at these prices will be handsomely rewarded as the deals start to flow”. These prices are currently circa 12p. But those who bought in late teens will also be well rewarded in my view as the deals flow.

We can’t forget that the price rose from circa 4p to briefly touch 20p before settling around 12-14p. That was all before the optimal launch which has since proven to be even more effective and we have confirmation that the NCI wishes to continue to use the platform for years to come.

Good post GTC.

And for all those reasons, folk buying at these prices will be handsomely rewarded as the deals start to flow. Still don’t think investors have woken up to just how huge Optimal is.

Won’t be long before a big pharma comes calling to take us out at a very substantial premium to current micro cap. Adrian even alluded to it in one of the presentations. Either way could be ab exciting week with results, investor presentation and collaboration agreement with NCI needing to be put on commercial terms before end of the week when current deal runs out.